NCT05108623: A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors

NCT05108623
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have progressed on Keytruda/pembrolizumab or Opdivo/nivolumab to be eligible for Part 2 of the study
Exclusions: Patients with untreated brain and/or leptomeningeal metastases
https://ClinicalTrials.gov/show/NCT05108623

Comments are closed.

Up ↑